PCOS Is Now PMOS: What the Name Change Means for Your Clinical Practice
Polycystic Ovary Syndrome has been officially renamed Polyendocrine Metabolic Ovarian Syndrome. Here is what the PMOS name change means for your clinical practice.
Polycystic Ovary Syndrome (PCOS) has been officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). The name change was published in The Lancet on May 12, 2026 and endorsed by a coalition of 56 global clinical and patient organizations including the Endocrine Society and the International Androgen Excess and PCOS Society.
This is not a cosmetic change. It is a clinical reframing that has significant implications for how this condition is diagnosed, treated, and understood, and it matters deeply for nurse practitioners practicing integrative and functional medicine.
Why the Name Changed
The old name, polycystic ovary syndrome, implied that ovarian cysts were the defining feature of the condition. They are not. Many women with PCOS never develop cysts. Many women with cysts do not have PCOS. The name contributed to missed diagnoses, fragmented care, and a narrow reproductive framing that left the metabolic and endocrine drivers of the condition largely unaddressed.
The new name, polyendocrine metabolic ovarian syndrome, reflects what the clinical evidence has supported for years: this is a complex, multi-system condition involving hormonal dysregulation, insulin resistance, cardiometabolic risk, inflammatory burden, and reproductive dysfunction. It is not primarily a gynecological disorder. It is an endocrine and metabolic disorder with reproductive consequences.
What PMOS Looks Like Clinically
The presentation has not changed. Your patients with PMOS may present with:
- Irregular or absent menstrual cycles
- Androgen excess including acne, hirsutism, and hair loss
- Insulin resistance and weight gain
- Mood dysregulation and anxiety
- Elevated cardiometabolic risk
The diagnosis criteria remain the same. What changes is the clinical lens through which you interpret and treat the condition.
When you understand PMOS as a polyendocrine metabolic disorder, the treatment approach shifts naturally toward root cause resolution, including insulin sensitization, HPA axis support, anti-inflammatory interventions, and hormonal rebalancing, rather than symptom management alone.
What This Means for Your Practice
Both PMOS and PCOS will be used interchangeably during a three-year transition period. You will see both terms in clinical settings, insurance documentation, and patient education materials. Update your intake forms and patient handouts as you are able, and begin introducing the new terminology to patients with a brief explanation of why the name changed.
More importantly, use this moment as a teaching opportunity. The name change validates the systems-based approach to women’s hormonal health that integrative nurse practitioners have been practicing for years. The conventional medical world is catching up to what functional medicine has long understood, that hormones, metabolism, inflammation, and reproductive health are inseparable.
For NPs Using BridgeWell Curriculum
The PMOS name change will be incorporated into BridgeWell curriculum updates. In the meantime, when you encounter PCOS in course materials, understand that you are studying what is now officially called PMOS. The clinical content, the root cause framework, and the treatment approach remain the same and remain current.
Written by Dr. Sheri Erwin, DNP, APRN, FNP-C
Founder, BridgeWell Integrative Education. 30+ years in healthcare, 16+ years training nurse practitioners. Systems-based, CE-accredited, and designed for NP scope from the ground up.
This Is What BridgeWell Clinical Depth Looks Like in Every Course.
Every BridgeWell course is built on the systems-based reasoning you just read about, applied to real patients and designed for NP scope.
